Alumis Inc. (NASDAQ:ALMS) CEO Acquires $100,786.00 in Stock

Alumis Inc. (NASDAQ:ALMS) CEO Martin Babler bought 15,650 shares of the business’s stock in a transaction on Tuesday, April 1st. The stock was bought at an average price of $6.44 per share, with a total value of $100,786.00. Following the transaction, the chief executive officer now owns 106,454 shares in the company, valued at approximately $685,563.76. This represents a 17.23 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Alumis Price Performance

Shares of NASDAQ ALMS opened at $10.05 on Friday. The business’s 50-day simple moving average is $5.52 and its 200-day simple moving average is $8.22. Alumis Inc. has a 52 week low of $3.18 and a 52 week high of $13.53.

Hedge Funds Weigh In On Alumis

Institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets bought a new stake in shares of Alumis during the 3rd quarter worth $27,000. Wells Fargo & Company MN raised its stake in Alumis by 77.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock valued at $69,000 after purchasing an additional 3,823 shares during the last quarter. Northern Trust Corp boosted its holdings in Alumis by 4.3% in the 4th quarter. Northern Trust Corp now owns 111,326 shares of the company’s stock valued at $875,000 after purchasing an additional 4,587 shares during the period. Charles Schwab Investment Management Inc. grew its position in Alumis by 4.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 113,401 shares of the company’s stock worth $891,000 after purchasing an additional 4,808 shares during the last quarter. Finally, Barclays PLC increased its holdings in shares of Alumis by 33.9% during the 4th quarter. Barclays PLC now owns 24,581 shares of the company’s stock worth $193,000 after purchasing an additional 6,221 shares during the period.

Analyst Upgrades and Downgrades

ALMS has been the topic of a number of research reports. Oppenheimer began coverage on shares of Alumis in a research note on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a research report on Thursday, March 20th. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Alumis in a report on Wednesday, March 26th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $26.00.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.